ArticleClinical and translational allergy2025

Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.

Clive Grattan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.